COVID-19 Pre-Clinical Therapeutics/Drug and Vaccine Research
Exploiting in silico immuno-informatics, we develop an AI framework to predict and select the best vaccine subunits and construct a multi-epitope vaccine for emerging SARS-CoV-2 virus. Learn more.
Network for Cardiothoracic Surgical Investigations in Cardiovascular Medicine: Mesenchymal Stem Cells for the Treatment of Moderate to Severe COVID-19 Acute Respiratory Distress Syndrome
Therapeutic targeting of SARS-CoV-2 main protease with ultrastable microproteins
Off-the-shelf cellular immunotherapy for COVID-19
Development of mucosal COVID-19 vaccines
Blocking COVID-19 from entering into lung cells and providing lung cells and organoids for developing drugs for preventing COVID-19 transmission and cytokine storm.
Development of TMPRSS2 antibody as an antiviral treatment for SARS-CoV-2 (COVID-19).
Non-clinical development of monothiol human thioredoxin-1 (ORP100S) as an inhaled treatment for COVID-19 respiratory disease.
Identified a library of drug-like compounds to facilitate degradation or inhibit translation of the SARS-CoV-2 RNA genome.
Developing novel small molecule immunomodulators to inhibit cytokine storm and lung damage in COVID-19 and similar infections.
Developing antiviral molecules against COVID-19.
Development of a host PIKFYVE kinase inhibitor for the treatment of COVID-19.
Investigating side effects of antiviral drugs and minimizing them.
Prevention and Treatment of COVID-19 Induced Pneumonia by Stimulating the Protective Arm of Angiotensin System
Evaluation of Telmisartan for COVID-19 Disease
Drug to reduce SARS-CoV-2-related disease severity induced by alcohol and tobacco
Targeting RNA methyltransferase and entry to derepress anti-SARS-CoV-2 defense
Repurposing potent antiviral agents for COVID-19.
Dasatinib for the treatment of patients with moderate to severe SARS-CoV2 (COVID-19)
Developing peptide and protein reagents for COVID-19 serological testing and therapeutics.
Creating live hybrid viruses toward an effective COVID-19 vaccine.